electroCore,

electroCore, P/CF

The P/CF (Price-to-Cash-Flow Ratio) of electroCore, (ECOR) as of Oct 17, 2026 is -6.40. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -7.54 — a change of -15.13% (higher).

P/CF

-6.40

YoY

-15.13%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of electroCore, is 2025 -6.40 . P/CF (Price-to-Cash-Flow Ratio) of electroCore, was 2024 -7.54 . It decreases by -15.13% higher compared to the previous year.

The electroCore, P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-1.11 USD
Jan 1, 2019
-1.16 USD
Jan 1, 2020
-2.61 USD
Jan 1, 2021
-3.85 USD
Jan 1, 2022
-3.15 USD
Jan 1, 2023
-3.57 USD
Jan 1, 2024
-7.54 USD
Jan 1, 2025
-6.40 USD
The electroCore, P/CF history
YEARP/CFYoY
-6.40-15.13%
-7.54+111.11%
-3.57+13.48%
-3.15-18.13%
-3.85+47.14%
-2.61+124.76%
-1.16+4.54%
-1.11-46.23%
-2.07-47.78%
-3.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

P/CF (Price-to-Cash-Flow Ratio) of electroCore, is -6.40 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of electroCore, changed from -7.54 to -6.40, representing a -15.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) electroCore, since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s electroCore, with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — electroCore,

All Key Metrics — electroCore,